Arcus Biosciences, Inc. - 8-K Filing

Arcus Biosciences presented new clinical data on casdatifan for clear cell renal cell carcinoma at an event. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $RCUS

Read the full article at SEC EDGAR

More Regulatory news